基础医学与临床 ›› 2011, Vol. 31 ›› Issue (4): 454-457.

• 短篇综述 • 上一篇    下一篇

MicroRNA103的研究进展

余东琪1,周怀君2   

  1. 1. 东南大学临床医学院
    2. 鼓楼医院
  • 收稿日期:2010-07-09 修回日期:2010-08-25 出版日期:2011-04-05 发布日期:2011-04-08
  • 通讯作者: 周怀君 E-mail:zhouhj2007@126.com
  • 基金资助:
    省科技发展项目

Advance in the Research of microRNA103

YU Dong-qi 1,ZHOU Huai-jun 2   

  1. 1. Medical College of Southeast University
    2. GuLou Hospital
  • Received:2010-07-09 Revised:2010-08-25 Online:2011-04-05 Published:2011-04-08
  • Contact: ZHOU Huai-jun E-mail:zhouhj2007@126.com

摘要: 微小RNA(miRNAs)是一类长度为22nt左右的高度保守的内源性小分子非编码RNA,通过与靶基因的3'-UTR结合,对靶基因进行切割或翻译抑制。miR-103作为microRNA家族中重要的一员,不仅在子宫内膜癌、卵巢癌、白血病、胰腺癌、膀胱癌等多种肿瘤中发挥调控作用,且在糖脂代谢、无脑畸形的发病等方面有着潜在的作用。

关键词: microRNA, miR-103, 肿瘤, 糖脂代谢, 神经系统

Abstract: MicroRNAs (miRNAs) are a group of small noncoding RNAs of about 22 nucleotides in length, which mediate the post-transcriptional gene modulation by annealing to incomplete complementary sequences in the 3’untranslated regions of target mRNAs. miR-103 as an important member of microRNA family, plays a regulatory role in multiple tumors; it also has a potential role in non-tumor diseases.

中图分类号: